Teva Pharma (TEVA) Numbers Ratcheted Higher at Citi on Bullish Copaxone News
Get Alerts TEVA Hot Sheet
Price: $14.11 -2.22%
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Rating Summary:
12 Buy, 25 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Shares of Teva Pharma (NYSE: TEVA) are mildly lower today (-0.6%) despite bullish commentary at Citigroup with the Copaxone bull case thesis materializing. Citi analyst Liav Abraham reiterated a Buy rating and boosted the price target on the stock from $56 to $70.
Liav said, "Today’s decision by the US Supreme Court to hear Teva's appeal regarding the previously invalidated Copaxone '808 patent shifts Copaxone from an "at-risk" to a largely sustainable franchise for Teva over the near to medium term, we believe. The ramifications of today’s announcement are multifactorial for Teva, and include (i) upside to the ongoing conversion of Copaxone 20mg patients to the 40mg
formulation; (ii) enhanced free cash flow generation for Teva, implying greater
financial flexibility.
Teva remains the firm's preferred name in the multinational generics space and is on Citi's US Focus List. The firm raised FY 2014 EPS from $4.67 to $5.21 (cons $4.56), FY 2015 EPS from $4.60 to $5.40 (cons $4.54), FY 2016 EPS from $4.66 to $5.52 (cons $4.58).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $52.84 yesterday.
Liav said, "Today’s decision by the US Supreme Court to hear Teva's appeal regarding the previously invalidated Copaxone '808 patent shifts Copaxone from an "at-risk" to a largely sustainable franchise for Teva over the near to medium term, we believe. The ramifications of today’s announcement are multifactorial for Teva, and include (i) upside to the ongoing conversion of Copaxone 20mg patients to the 40mg
formulation; (ii) enhanced free cash flow generation for Teva, implying greater
financial flexibility.
Teva remains the firm's preferred name in the multinational generics space and is on Citi's US Focus List. The firm raised FY 2014 EPS from $4.67 to $5.21 (cons $4.56), FY 2015 EPS from $4.60 to $5.40 (cons $4.54), FY 2016 EPS from $4.66 to $5.52 (cons $4.58).
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $52.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- Teleperformance (TEP:FP) (TLPFY) PT Lowered to EUR125 at RBC Capital, 'perceived risk profile makes it a no-fly zone for many investors'
- Walt Disney (DIS) PT Raised to $145 at Needham
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, Hot CommentsRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!